Drug intelligence / Profile preview

BST08

Development stage: Phase 1
Lead developer: Biosyngen
Modality: Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

BST08 is a T-lymphocyte cell therapy developed for the treatment of cancer, specifically targeting neoplasms such as non-small cell lung cancer and liver cancer. The drug functions as a T lymphocyte replacement therapy, aiming to restore or enhance the immune system's ability to recognize and attack tumor cells. It is being developed by Guangzhou BioSyngen Co., Ltd. and BioSyngen Pte Ltd., with clinical trials currently underway for advanced non-small cell lung cancer. The mechanism of action involves the use of ex vivo manipulated T lymphocytes to replace or supplement endogenous T-cell function in patients whose immune systems are compromised by malignancy[1][2].

Other names: BST008BST-008BST 008

Beyond the preview

Go deeper on BST08.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BST08.

Explore the full profile